Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Terminated Initiated May 22, 2017 (9 years ago)

Caffeine Powder

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

Marketed without an Approved NDA/ANDA: The product consists of pure, powdered caffeine and is an unapproved drug due to stimulant claims. The product is also misbranded as it fails to bear adequate directions for its intended use.

Cause type: Unapproved drug

The product was marketed without an approved NDA/ANDA, or does not meet the OTC monograph it claims to follow. Nothing about the product - dose, purity, safety - has been reviewed by FDA, so the claims on the box are unverified. All unapproved drug recalls.

What was recalled

Caffeine Powder, Anhydrous, Pharmaceutical Grade, 100% Pure caffeine, 250 g (8.8 oz)., 1250 servings, Packed By: LifeLine Nutrients Corp, 1801 S. Canal St, Chicago, IL 60616, UPC 021754905076

Drug: Caffeine

Recalling firm
Global Marketing Enterprises, Inc.
Origin
IL, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-1096-2017 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Caffeine recalls

See all
Class II · Moderate risk

Acetaminophen 500mg Caffeine 65mg caplets

Labeling: Label Mix-up. This issue affects the outer box labeling only. The box incorrectly states the ingredients Acetaminophen 500mg and Caffeine 65mg. The inner pouch correctly states the ingredients are Aspirin (NSAID)*500mg and Caffeine 32.5mg.

Ongoing Labeling / mix-up Aero Healthcare NDC 55305-135-01 D-0155-2026
Class I · High risk

Healthy Living Acetaminophen

Labeling: Missing Label - some bottles are missing the the manufacturers label that includes the drug facts information.

Ongoing Labeling / mix-up Aurobindo Pharma USA Inc NDC 58602-882-21 D-0641-2024
Class II · Moderate risk

Migrenol Caplet

CGMP Deviations

Terminated cGMP deviation ULTRAtab Laboratories, Inc. NDC 62959-565-00 D-0547-2022

Other unapproved drug recalls from 2017

All unapproved drug recalls
Class III · Low risk

Gabapentin Oral Solution

CGMP Deviations: Inadvertent release of a drug product with unapproved active ingredient manufacturer.

Terminated Unapproved drug Akorn Inc D-0211-2018
Class III · Low risk

Meclizine hydrochloride tablets USP

Marketed without an approved NDA/ANDA: Bottles were released prior to final approval.

Terminated Unapproved drug Jubilant Cadista Pharmaceuticals, Inc. NDC 59746-122-06 D-0082-2018